Longitudinal dynamics and clinically available predictors of poor response to COVID-19 vaccination in multiple myeloma

Gaurav Agarwal; Sally Moore; Ross Sadler; Sherin Varghese; Alison Turner; Lucia Y Chen; Jemma Larham; Nathanael Gray; Oluremi Carty; Joe Barrett; Constantinos Koshiaris; Jaimal Kothari; Stella Bowcock; Udo Oppermann; Vicky Gamble; Gordon Cook; Chara Kyriakou; Mark Drayson; Supratik Basu; Sarah McDonald; Shelagh McKinley; Sarah Gooding; Muhammad K Javaid; Karthik Ramasamy

doi:10.3324/haematol.2023.284286

Longitudinal dynamics and clinically available predictors of poor response to COVID-19 vaccination in multiple myeloma

Haematologica. 2024 Jun 1;109(6):1960-1965. doi: 10.3324/haematol.2023.284286.

Authors

Gaurav Agarwal¹, Sally Moore², Ross Sadler³, Sherin Varghese³, Alison Turner⁴, Lucia Y Chen³, Jemma Larham³, Nathanael Gray⁴, Oluremi Carty³, Joe Barrett⁴, Constantinos Koshiaris⁵, Jaimal Kothari³, Stella Bowcock⁶, Udo Oppermann⁴, Vicky Gamble⁴, Gordon Cook⁷, Chara Kyriakou⁸, Mark Drayson⁹, Supratik Basu¹⁰, Sarah McDonald¹¹, Shelagh McKinley¹², Sarah Gooding¹³, Muhammad K Javaid⁴, Karthik Ramasamy¹⁴

Affiliations

¹ Division of Haematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
² Bath Royal United Hospitals, Bath.
³ Oxford University Hospitals NHS Trust, Oxford.
⁴ Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford.
⁵ Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford.
⁶ King's College Hospital NHS Trust, London.
⁷ Leeds Institute of Clinical Trials Research, University of Leeds, Leeds.
⁸ University College London Hospitals NHS Trust, London.
⁹ University of Birmingham, Birmingham.
¹⁰ The Royal Wolverhampton NHS Trust, Wolverhampton, UK; University of Wolverhampton, Wolverhampton.
¹¹ Blood Cancer UK, London.
¹² Myeloma UK, Edinburgh.
¹³ Oxford University Hospitals NHS Trust, Oxford, UK; MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine.
¹⁴ Oxford University Hospitals NHS Trust, Oxford. [email protected].

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
COVID-19 Vaccines* / administration & dosage
COVID-19 Vaccines* / immunology
COVID-19* / epidemiology
COVID-19* / prevention & control
Female
Humans
Longitudinal Studies
Male
Middle Aged
Multiple Myeloma* / immunology
Multiple Myeloma* / therapy
SARS-CoV-2* / immunology
Vaccination*

Substances

COVID-19 Vaccines

Grants and funding

Funding: The work was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). Funding for this study has been received from Blood Cancer Vaccine Consortium, Myeloma UK and Janssen UK. The RUDY platform has been funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.